# chronic hepatitis B FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-hepatitis-b

> No upcoming FDA catalysts in chronic hepatitis B; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 20, 2026 | [HIBSAGO (bepirovirsen) FDA approval](https://sec-api.dev/pdufa/bepirovirsen) | GSK | chronic hepatitis B | completed, approved | "Hibsago \| bepirovirsen \| 10/20/2026 \| To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| October 27, 2026 | [Taf primary completion](https://sec-api.dev/pdufa/taf) | GILD | Chronic Hepatitis B | completed | "NCT02932150 (Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02932150)) |
| Oct 2026 to Jan 2027 | [Taf topline data readout](https://sec-api.dev/pdufa/taf) | GILD | Chronic Hepatitis B | scheduled | "NCT02932150 (Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02932150)) |

## Drugs

- [HIBSAGO (bepirovirsen)](https://sec-api.dev/pdufa/bepirovirsen) (GSK)
- [Taf](https://sec-api.dev/pdufa/taf) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-hepatitis-b.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "chronic hepatitis B FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-hepatitis-b

```bibtex
@misc{secapidev_indications_chronic_hepatitis_b_20261116,
  title        = {chronic hepatitis B FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-hepatitis-b}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_hepatitis_b_20261116","title":"chronic hepatitis B FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-hepatitis-b","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
